Promoting evidence-based management of anemia in cancer patients: Concurrent and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines for supportive care in cancer

Supportive Care in Cancer

Volumn 18, Issue 7, 2010, Pages 847-858

  Van Erps, Joanna ^a   Aapro, Matti ^b   MacDonald, Karen ^c   Soubeyran, Pierre ^d,e   Turner, Matthew ^f   Warrinnier, Hans ^g   Albrecht, Tara ^h   Abraham, Ivo ^c,i  

^a Algemeen Stedelijk Ziekenhuis   (Belgium)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c Matrix45 ^*  (United States)

^d INSTITUT BERGONIÉ   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g Roche Pharmaceuticals   (Belgium)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

Author keywords

Anemia; Computerized decision support; Erythropoietic proteins; Practice guidelines; Supportive cancer care

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEMOGLOBIN; HORMONE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PREDNISONE; RITUXIMAB; TOPOTECAN; TRASTUZUMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; DECISION SUPPORT SYSTEM; DISCRIMINANT VALIDITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

EID: 77953613259     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0718-z     Document Type: Article

References (30)

1. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616-1634
2. Ludwig H, Van Belle S, Barrett-Lee P et al (2004) The European Cancer Anemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients. Eur J Cancer 40:2293-2306
3. Blohmer JU, Dunst J, Harrison L et al (2005) Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 68:S12-S21
4. Caro JJ, Salas M, Ward A et al (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91:2214-2221
5. Nissenson AR, Goodnough LT, Dubois RW (2003) Anemia: not just an innocent bystander? Arch Int Med 163:1400-1404
6. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25:S43-S46
7. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083-4107
8. Rizzo JD, Somerfield MR, Hagerty KL et al (2008) Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26:132-149
9. Bokemeyer C, Aapro MS, Courdi A et al (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201-2216
10. Bokemeyer C, Aapro MS, Courdi A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258-270
11. Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13:33-36
12. Ludwig H, Aapro M, Bokemeyer C et al (2009) Treatment patterns and outcomes in the management of cancer-related anemia in Europe: findings from the Anemia Cancer Treatment (A.C.T.) study. Eur J Cancer. doi:10.1016/j.ejca.2009. 02.003
13. Aapro M, Abraham I, MacDonald K et al (2007) Intraclass correlation metrics for the accuracy of algorithmic definitions in a computerized decision support system for supportive cancer care. Support Care Cancer 15:1325-1329
14. Timmermans S, Mauck A (2005) The promises and pitfalls of evidence-based medicine. Health Aff 24:18-28
15. Eddy DM (2005) Evidence-based medicine: a unified approach. Health Aff 24:9-17
16. Olivotto A, Coldman AJ, Hislop TG (1997) Compliance with practice guidelines for node-negative breast cancer. J Clin Oncol 15:216-222
17. Hebert-Croteau N, Brisson J, Latreille J et al (2004) Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. J Clin Oncol 22:3685-3693
18. Mille D, Roy T, Carrere MO et al (2000) Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French comprehensive cancer center. J Clin Oncol 18:1718-1724
19. Cruse H, Winiark M, Marshburn J et al (2002) Quality and methods of developing practice guidelines. BMC Health Serv Res 2:1-7
20. Aapro M, Van Erps J, MacDonald K et al (2008) Promoting evidence-based management of anemia in cancer patients: background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines. Crit Rev Oncol Hematol 65:32-42
21. Smith TJ, Hillner BE (2001) Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol 19:2886-2897
22. Bates DW, Kuperman GJ, Wang S et al (2003) Ten commandments for effective clinical decision making support: making the practice of evidence-based medicine a reality. J Am Med Inform Assoc 10:523-530
23. Musen MA, Shahar Y, Shortliffe EH (2006) Clinical decision support systems. In: Shortliffe EH, Cimino JJ (eds) Biomedical informatics: computer applications in health care and biomedicine, 3rd edn. Springer, New York, pp 698-736
24. Kawamoto K, Houlihan CA, Balas EA et al (2005) Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. Br Med J 330:775-782
25. Aapro M, MacDonald K, Van Erps J et al (2009) Managing cancer-related anemia in congruence with the EORTC guidelines is an independent predictor of hemoglobin outcome: initial evidence from the RESPOND study. Eur J Cancer 45:8-11
26. Khuri FR (2007) Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356:2445-2448
27. Anonymous (2008) Erythropoietin analogues: an unnecessary class of drugs. Lancet Oncol 9:81
28. Aapro MS, Birgegard G, Bokemeyet C et al (2008) Erythropoietins should be used according to guidelines. Lancet Oncol 9:412-413
29. Tonelli M, Hemmelgarn B, Reiman T et al (2009) Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. Can Med Assoc J 180(11):E62-E71. doi:10.1503/cmaj.090470
30. Bohlius J, Schmidlin K, Brillant C et al (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373:1532-1542